PARIS--(BUSINESS WIRE)--Today ANJAC Health & Beauty (ANJAC) announced its acquisition of Pillar5 Pharma (Pillar5), one of the primary manufacturers (CDMOs) specializing in the production of sterile ophthalmic solutions and niche solid dose manufacturing (tablets, capsules etc.). The acquisition reinforces ANJAC’s international expansion and broadens its health offerings with new ophthalmic services for local and international brands and laboratories. This is ANJAC’s second major operation of 2022, following its acquisition of Apollo Healthcare in January.
TORONTO--(BUSINESS WIRE)--Apollo Healthcare Corp. (TSX: AHC, OTCQX: AHCCF) (“Apollo” or the “Company”) and Anjac SAS (“Anjac”) are pleased to announce that they have completed the previously announced plan of arrangement (the “Arrangement”) under section 182 of the Business Corporations Act (Ontario) (“OBCA”) among Apollo, Anjac and 1000009701 Ontario Inc. (the “Purchaser”), pursuant to which, among other things, the Purchaser has acquired all of Apollo’s issued and outstanding Class B shares (“Apollo Shares”) other than certain Apollo Shares held by Charles Wachsberg and Richard Wachsberg.